WINT vs. SRZN, INKT, PLUR, ACHL, CRTX, INAB, TARA, ZIVO, CYTH, and EVAX
Should you be buying Windtree Therapeutics stock or one of its competitors? The main competitors of Windtree Therapeutics include Surrozen (SRZN), MiNK Therapeutics (INKT), Pluri (PLUR), Achilles Therapeutics (ACHL), Cortexyme (CRTX), IN8bio (INAB), Protara Therapeutics (TARA), ZIVO Bioscience (ZIVO), Cyclo Therapeutics (CYTH), and Evaxion Biotech A/S (EVAX). These companies are all part of the "medical" sector.
Surrozen (NASDAQ:SRZN) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation, community ranking and media sentiment.
Surrozen and Windtree Therapeutics both received 3 outperform votes by MarketBeat users. However, 50.00% of users gave Windtree Therapeutics an outperform vote while only 16.67% of users gave Surrozen an outperform vote.
Windtree Therapeutics has lower revenue, but higher earnings than Surrozen. Surrozen is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.
Surrozen has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.
In the previous week, Surrozen and Surrozen both had 1 articles in the media. Surrozen's average media sentiment score of 1.00 beat Windtree Therapeutics' score of -1.00 indicating that Windtree Therapeutics is being referred to more favorably in the news media.
66.6% of Surrozen shares are held by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are held by institutional investors. 35.0% of Surrozen shares are held by company insiders. Comparatively, 0.5% of Windtree Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Windtree Therapeutics' return on equity of -82.43% beat Surrozen's return on equity.
Summary
Surrozen beats Windtree Therapeutics on 6 of the 11 factors compared between the two stocks.
Get Windtree Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding WINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Windtree Therapeutics Competitors List
Related Companies and Tools
